Pure Extracts Unveils Plans for Functional Mushrooms


Ryan Allway

November 30th, 2020

App, Exclusive, Psychedelics, Top Story


 

There are more than 2,000 species of edible fungi and at least 15 have functional benefits that support overall health. Like other superfoods, functional mushrooms have antioxidant properties that support the immune system, dietary fiber to aid in healthy digestion and numerous other benefits to everything from mental clarity to skin health.

At the same time, there has been a growing interest in psychedelic mushrooms, such as psilocybin, for the treatment of a wide range of mental health disorders. The FDA has already granted breakthrough therapy status to several clinical trial candidates while reports suggest that the global functional mushroom market could reach $34.3 billion by 2024.

Pure Extracts Technologies Corp. (CSE: PULL) (XFRA: A2QJAJ) has recognized these trends and begun to expand its business model to include mushroom formulations through the use of extraction processes that have proven compatible with its existing infrastructure.

Let’s take a closer look at these plans and why investors should pay close attention.

Click here to receive and investor presentation and corporate updates

Functional Mushroom Products

Pure Extracts has built a business around extracting cannabinoids from hemp and cannabis plants. After several inquiries about functional mushrooms, the Company has begun expanding its efforts to develop pill, capsule and edible products from lion’s mane, turkey tail, reishi and other products both under its own brand and on behalf of third parties. 

“Moving into the field of mushroom extractions is an obvious and exciting opportunity to leverage our advanced technology and proven capabilities,” said CEO Ben Nikolaevsky. “We look forward to launching our functional products commercially in the next few months and can’t help but to see similarities to the cannabis sector.”

The Company’s in-house Pure Mushrooms brand will begin selling products by the end of the first quarter of next year through direct-to-consumer means, including its capital-efficient e-commerce portal. In addition, the Company signed a LOI with one of Canada’s leading functional mushroom wellness brands to co-develop CBD-enhanced mushroom products.

Click here to receive and investor presentation and corporate updates

Expansion into Psychedelics 

Psychedelic medicine has become one of the hottest areas of medicine. While psychedelics were formerly off-limits to researchers, the liberalization of drug laws put psychedelic medicines into the hands of researchers that have discovered a potentially far-reaching mechanism of action in the treatment of numerous mental health disorders. 

Pure Extracts plans to eventually enter the growing field of psychedelic mushroom processing as an additional part of its diverse extraction market penetration strategy. CEO Nikolaevsky said that he sees similarities to the cannabis sector regarding the pathways to both medicinal and recreational legalization within the burgeoning space. 

Psilocybin has already shown tremendous promise in the treatment of depression, anxiety, post-traumatic stress disorder, bipolar disorder, Alzheimer’s disease, and addiction. With the FDA supportive of clinical trials, the first approved products could begin to reach patients by next year, when commercialization will begin to take place.

Looking Ahead

Pure Extracts Technology Corp. (CSE: PULL) (XFRA: A2QJAJ) has already built an impressive operation targeting cannabis and hemp extraction and is beginning to position itself to take advantage of the demand for functional mushroom extracts. With an initial focus on functional mushrooms, management plans on eventually reaching into the nascent psychedelics space.

For more information, visit the Company’s website or download their investor presentation.

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading